Chemists have cracked a decades-old puzzle: how to selectively modify carborane molecules without resorting to expensive metal catalysts. Researchers from the University of Barcelona, the University of Girona, and Nanjing University have developed a metal-free method using hypervalent iodine reagents that unlocks new possibilities for treating cancer and detecting contaminants at the molecular level.
Carboranes—molecular clusters made of carbon, boron, and hydrogen atoms—have long intrigued scientists because of their remarkable properties. They remain stable at extreme temperatures and under radiation, and they can bind to biological molecules in precise ways. One of their most promising applications is in boron neutron capture therapy (BNCT), an experimental radiotherapy that attacks cancer cells with remarkable selectivity. Yet despite their potential, these molecules have been frustratingly difficult to chemically modify because their boron-hydrogen bonds are nearly identical to one another, making targeted editing feel like finding a single thread in a tightly woven tapestry.
The breakthrough came through an unexpected discovery. The research team, led by theoretical chemist Jordi Poater at the University of Barcelona's Department of Inorganic and Organic Chemistry, and computational specialist Miquel Solà at the University of Girona, working with synthesis expert Hong Yan at Nanjing University, found that hypervalent iodine reagents could selectively activate these stubborn bonds under mild, benign conditions. More remarkably, they uncovered an unprecedented interaction between the boron cage structure and iodine that enables the formation of entirely new chemical bonds—boron-oxygen, boron-nitrogen, boron-sulfur, and boron-phosphorus connections that were previously out of reach.
This discovery builds on earlier work by the same team that identified a previously unknown migration process within the boron cage itself, opening up positions for functionalization that conventional chemistry simply couldn't access. Poater's theoretical modeling proved crucial in explaining not just how these reactions work, but why they achieve such striking selectivity—a level of understanding that paves the way for rational design of new molecules.
The practical implications are immediate and significant. The team has already used the new methodology to prepare boron-containing compounds with real therapeutic promise: improved agents for boron neutron capture therapy that could offer hope to cancer patients, and sophisticated luminescent materials capable of detecting oxygen and generating reactive oxygen species for sensing applications. These aren't theoretical possibilities—they're working prototypes with tangible medical and industrial relevance.
What makes this advance particularly elegant is its simplicity. By avoiding metal catalysts entirely, the method is more cost-effective and environmentally conscious than existing approaches. It gives chemists what Poater calls "a new and versatile tool" for designing functional boron-based molecules. For materials scientists, this opens doors to advanced sensors. For oncologists, it promises enhanced treatments for a disease that kills millions annually. The publication, which appeared in Angewandte Chemie International Edition in 2026, represents the kind of foundational chemistry that transforms from laboratory curiosity into clinical reality over the coming years.